Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Apr 28, 2008; 14(16): 2544-2549
Published online Apr 28, 2008. doi: 10.3748/wjg.14.2544
Published online Apr 28, 2008. doi: 10.3748/wjg.14.2544
Table 3 Remission and response rates at 8 wk to infliximab in the UC patients and colectomy rates at 6 mo and 12 mo
| Disease type | Response | Remission | Colectomy | Colectomy |
| wk 8 | wk 8 | ≤ 6 mo | ≤ 12 mo | |
| E1 - proctitis | 0% | 0% | 0% | 100% |
| (0/1) | (0/1) | (0/1) | (1/1) | |
| E2 - left sided | 0% | 0% | 100% | 100% |
| (0/1) | (0/1) | (1/1) | (1/1) | |
| E3 - extensive | 100% | 46.20% | 23.10% | 46.10% |
| (13/13) | (6/13) | (3/13) | (6/13) | |
| Total | 86.70% | 40.00% | 26.70% | 53.30% |
| (13/15) | (6/15) | (4/15) | (8/15) |
- Citation: Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14(16): 2544-2549
- URL: https://www.wjgnet.com/1007-9327/full/v14/i16/2544.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.2544